Lisa Sher

Lisa Sher has a diverse and extensive work experience in the field of investor relations and corporate development. Lisa is currently serving as the Head of Corporate Development at SteroTherapeutics since June 2022. Prior to this, they worked as the SVP at Tiberend Strategic Advisors, Inc. starting from May 2021.

Lisa has also held positions in several other organizations, including Stern Investor Relations where they served as the Managing Director from November 2020 to March 2021. Before that, they were a Senior Vice President at Argot Partners, LLC from December 2019 to November 2020. Lisa also worked as the Senior Director of Investor Relations and Communications at Opiant Pharmaceuticals from June 2019 to November 2019.

In addition, Lisa has held various investor relations roles in different companies. Lisa was the Head of Investor Relations at AC Immune from September 2017 to June 2019 and a Senior Investor Relations Advisor at MBS Value Partners from June 2016 to September 2017.

Lisa began their career in investor relations as a Senior Investor Relations Associate at MBS Value Partners from September 2013 to June 2014. Prior to that, they worked as a Director of Business Development at OneMedPlace from March 2010 to September 2013, where they successfully managed investor relations and created capital partnerships for emerging life science companies. Lisa also organized investor conferences such as OneMedForum in New York and San Francisco.

From June 2014 to June 2016, Lisa served as the Director of Investor Relations and Programming at the Biotechnology Innovation Organization. In this role, they managed all investor-related communications and led special events for the investment community.

Lisa Sher attended Boston University, where they pursued a Bachelor of Arts degree with a concentration in International Relations and Economics. The exact start and end years of their education at Boston University are not specified.